Clinical trial
PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed…
NCT00335868 · Jonsson Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00335868 |
|---|---|
| Title | PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy |
| Official title | A Pilot Phase II Study of PHA-739358 in Patients With Chronic Myeloid Leukemia Relapsing on Gleevec or c-ABL Therapy |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Other |
| Interventions | danusertib, laboratory biomarker analysis, pharmacological study |
| Enrollment | 16 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2009 |
| First posted | Jun 12, 2006 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: